Document is current
Any future updates will be listed below
-
Authors
Negrier, Sylvie
Bonastre, Julia
Colrat, Florian
Teitsson, Siguroli
Knight, Christopher
Ni, Lei
Chevalier, Julie
Branchoux, Sébastien
Rouprêt, Morgan
-
Funding
Funding for this research was provided by:
Bristol Myers Squibb
- License Information
-
More Information
Article History
Received: 13 August 2024
Accepted: 18 March 2025
First Online: 1 April 2025
Declarations
:
: SB, FC and ST are employees of Bristol Myers Squibb, who develop and market immunotherapies for the treatment of MIUC. JC was an employee of VYOO, a contract research organisation which received funding from Bristol Myers Squibb for carrying out this study. CK and LN are employees of RTI Health Solutions, a contract research organisation which received funding from Bristol Myers Squibb for carrying out this study. JB, SN and MR report consultancy fees from Bristol Myers Squibb in the context of this study. In addition, JB reports honoraria from Bristol Myers Squibb, Roche and MSD and grant (institution) from Bristol Myers Squibb. SN reports research funding (institution) from Pfizer and Ipsen and honoraria from Bristol Myers Squibb, Pfizer, Ipsen, Eisaï and Merck Sharpe and Dohme. MR reports serving on advisory boards for Astellas, Bristol Myers Squibb and Pfizer.
